Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

10 Sep 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).

10 Sep 2009

Manuka honey inhibits MRSA infections by killing bacterial proteins

Manuka honey may kill bacteria by destroying key bacterial proteins. Dr Rowena Jenkins and colleagues from the University of Wales Institute - Cardiff investigated the mechanisms of manuka honey action and found that its anti-bacterial properties were not due solely to the sugars present in the honey.

7 Sep 2009

Bloodstream infections can be avoided with a daily scrub solution bath

Giving critically ill hospital patients a daily bath with a mild, soapy solution of the same antibacterial agent used by surgeons to "scrub in" before an operation can dramatically cut down, by as much as 73 percent, the number of patients who develop potentially deadly bloodstream infections, according to a new study by patient safety experts at The Johns Hopkins Hospital and five other institutions.

5 Sep 2009

Touch of MIDAS to prepare the world for contagious outbreaks

To help the nation-and the world-understand and prepare for contagious outbreaks, the National Institutes of Health's Models of Infectious Disease Agent Study (MIDAS) adds new research expertise to increase its capacity to simulate disease spread, evaluate different intervention strategies and help inform public health officials and policymakers.

4 Sep 2009

Sodium chloride for treating head lice

At just 31 years of age, and with a first grader in tow, single mom Wendy Langley set out to take on the giants in the head lice industry. The reason? She couldn't, as she says, stand putting a popular but potentially toxic head lice treatment that "smelled like bug spray" on her kid's head to kill lice. Plus, she was constantly terrified the runny liquid would seep into her daughter's eyes.

4 Sep 2009

Sheller, P.C helps to settle the largest whistleblower complaint

Pfizer Inc. ignored a 2005 FDA Warning Letter to stop promoting its antibiotic Zyvox(R) as clinically superior to the significantly less expensive, generic vancomycin when its own FDA-approved label indicated otherwise. The drug giant also defrauded federal and state taxpayers by marketing Zyvox off-label, according to a qui tam whistleblower complaint filed by Philadelphia law firm Sheller, P.C. and other documents unsealed with today's $2.3 billion Pfizer settlement.

3 Sep 2009

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S. history.

3 Sep 2009

NAT gains importance as traditional testing methods become inadequate

An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).

28 Aug 2009

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.

28 Aug 2009

Enzymes could be targeted to kill dangerous pathogens

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens.

28 Aug 2009

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

27 Aug 2009

The SaniGuard dry-on-contact sanitising spray is launched by MisterSterile.com

A sanitising spray that kills 99.99% of Viruses, Bacteria and Germs is now available for purchase in the UK. The SaniGuard wipes, spray and fogger products were invented by David Morgan, president of DEM Technology in the United States. After patenting the product he was awarded EPA registration for its use on food contact surfaces in 1996.

25 Aug 2009

Research to be conducted on bacterial microbes in space to discover new medicines

Along with supply and equipment cargo bound for the International Space Station, Space Shuttle Discovery STS-128 will carry an additional scientific payload being conducted by Austin-based Astrogenetix, the first commercial space company to use microgravity to discover the foundation of new medicines.

25 Aug 2009

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

NovaBay(R) Pharmaceuticals, Inc., a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

24 Aug 2009

Marin Catholic High School's new SAS system reduces the presence of illness-causing microorganisms

Marin Catholic High School (MCHS) and CSG, the worldwide leader in environmentally-beneficial surface treatments, today announced the school is the Bay Area's first education facility to integrate the Surface Antimicrobial System (SAS). The most environmentally friendly and long-lasting treatment of its kind, SAS has transformed 10,000 square feet of high-touch surfaces in Marin's athletic facility into materials that continuously inhibit the growth of harmful bacteria, mold, and fungi for three years.

24 Aug 2009

MicroPhage's new platform for rapid identification of bacterial infections

MicroPhage announced today the launch of its multi-site clinical trial to support a U.S. Food and Drug Administration (FDA) premarket notification [510(k)]. The platform has been developed to rapidly identify bacterial infections and determine antibiotic susceptibility or resistance to aid physicians in antibiotic management.

21 Aug 2009

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Laboratories (NYSE:FRX) and AstraZeneca (NYSE:AZN) announced today they have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan.

12 Aug 2009

MRSA may follow hospital patients home

Infection with methicillin-resistant Staphylococcus aureus (MRSA) appears relatively common among patients discharged from the hospital into home health care, according to a report in the August 10/24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. In addition, about one-fifth of infected patients may transmit the organism to other people in their households.

10 Aug 2009

Staphylococcus aureus News and Research

Further Reading

NovaBay begins clinical studies for treating impetigo skin infection

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Manuka honey inhibits MRSA infections by killing bacterial proteins

Bloodstream infections can be avoided with a daily scrub solution bath

Touch of MIDAS to prepare the world for contagious outbreaks

Sodium chloride for treating head lice

Sheller, P.C helps to settle the largest whistleblower complaint

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

NAT gains importance as traditional testing methods become inadequate

Polymedix And UMass receive Phase I STTR contract for research on drug-resistant bacteria treatments

Enzymes could be targeted to kill dangerous pathogens

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

The SaniGuard dry-on-contact sanitising spray is launched by MisterSterile.com

Research to be conducted on bacterial microbes in space to discover new medicines

NovaBay Pharmaceuticals to deliver two poster presentations describing results from new studies of NVC-422

Marin Catholic High School's new SAS system reduces the presence of illness-causing microorganisms

MicroPhage's new platform for rapid identification of bacterial infections

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

MRSA may follow hospital patients home

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News